Inflammation Due to Ulcerative Colitis Treated by IL-7 Receptor Antagonist in Early Study

Inflammation Due to Ulcerative Colitis Treated by IL-7 Receptor Antagonist in Early Study
OSE Immunotherapeutics announced that its interleukin-7 (IL-7) receptor agonist, Effi-7, an immunomodulatory drug being developed for patients with ulcerative colitis, showed positive pre-clinical results. The findings were recently presented at the Federation of Clinical Immunology Societies 2016 Annual Meeting, held in Boston, in a poster titled "IL-7 receptor blockade prevents intestinal human T cells infiltration by modulation of alpha4-beta7 integrin expression." IL-7 is a potent immunostimulatory molecule that regulates immune cells. A number of studies in recent years have associated IL-7 with several autoimmune diseases, including ulcerative colitis. IL-7 is expressed by inflamed tissues, resulting in the recruitment of IL-7R-positive T-cells. These cells, in turn, activate other immune system cells and aggravate the inflammation, worsening the disease. OSE's Effi-7 is a monoclonal antibody directed at the human IL-7 receptor that, by blocking both IL-7 and the IL-7R internalization, induces a strong antagonist effect, resulting in a better control of T-cell recruitment. This approach is distinct from conventional treatment strategies, or from anti-inflammatory drugs currently in use, and has shown itself to be efficacious in restoring the normal activity of the immune system in autoimmune bowel diseases in several clinical models. Researchers from OSE demonstrated that Effi-7 therapy is effective in ulcerative colitis animal models by preventing the infiltration of T-cells into the intestine, reducing the inflammation-derived
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *